Milestone Pharmaceuticals Inc.
MISTNasdaq
$1.19
↓ -4.4%Jul 17 close · end-of-day
Price
1Y↓ -29.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$5.4M
Free Cash Flow (TTM)
-$51.5M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-14.9%
ROIC
—
Debt / Equity
1.6
Net Cash
$126.0M
Return 1Y
-28.2%
Company profile
Milestone Pharmaceuticals Inc. focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada.
- CEO
- Joseph G. Oliveto
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Headquarters
- Quebec
- Website
- milestonepharma.com
Management & directors
- Oliveto JosephPresident and CEO
- Bharucha DavidChief Medical Officer
- Hasija AmitCFO & EVP of Corp. Development
- Muller LorenzChief Commercial Officer
- Nelson Jeffrey EdwardChief Operating Officer
Roles derived from SEC Form 4 filings.
Earnings
MIST Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$238,000.00—
Diluted EPS-$0.20↓ -35.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$50.7M | -$43.1M | -$59.6M | -$61.1M | -$42.1M | -$62.1M |
| Net income | -$50.0M | -$42.9M | -$58.4M | -$59,685.00 | -$41,519.00 | -$63,058.00 |
| Diluted EPS | -$1.70 | -$1.02 | -$1.38 | -$1.39 | -$0.67 | -$0.75 |
| Operating cash flow | -$50.7M | -$33.2M | -$52.5M | -$46.4M | -$28.8M | -$49.0M |
| Free cash flow | — | — | -$52.7M | -$46.5M | -$28.9M | -$49.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | — | — | — | $238,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$9.7M | -$9.6M | -$12.3M | -$20.5M | -$12.5M | -$11.8M | -$17.3M | -$23.7M |
| Net income | -$9.4M | -$9.4M | $29.1M | -$20.8M | -$13.0M | -$11.9M | $45.6M | -$26.1M |
| Diluted EPS | -$0.14 | -$0.14 | -$0.18 | -$0.31 | -$0.20 | -$0.12 | -$0.12 | -$0.20 |
| Operating cash flow | -$6.1M | -$7.0M | -$6.8M | -$14.0M | -$12.6M | -$9.7M | -$12.8M | -$16.1M |
| Free cash flow | — | -$7.0M | — | -$14.0M | -$12.6M | -$9.8M | -$13.1M | -$16.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | -9942.4% |
| Net margin | — | — | — | — | — | — | — | -10952.1% |
Company news
May 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-16 | Oliveto Joseph· President and CEO | Sale | 36,500 | $2.26 | $82,490.00 | filing |
| 2026-01-26 | Oliveto Joseph· President and CEO | Sale | 34,523 | $1.93 | $66,629.39 | filing |
| 2026-01-26 | Bharucha David· Chief Medical Officer | Sale | 12,245 | $1.93 | $23,632.85 | filing |
| 2026-01-26 | Hasija Amit· CFO & EVP of Corp. Development | Sale | 12,245 | $1.93 | $23,632.85 | filing |
| 2026-01-26 | Nelson Jeffrey Edward· Chief Operating Officer | Sale | 12,245 | $1.93 | $23,632.85 | filing |
| 2026-01-26 | Muller Lorenz· Chief Commercial Officer | Sale | 11,180 | $1.93 | $21,577.40 | filing |
| 2026-01-26 | Muller Lorenz· Chief Commercial Officer | Option exercise | 20,100 | — | — | filing |
| 2026-01-26 | Hasija Amit· CFO & EVP of Corp. Development | Option exercise | 20,100 | — | — | filing |
| 2026-01-26 | Nelson Jeffrey Edward· Chief Operating Officer | Option exercise | 20,100 | — | — | filing |
| 2026-01-26 | Oliveto Joseph· President and CEO | Option exercise | 66,600 | — | — | filing |
| 2026-01-26 | Bharucha David· Chief Medical Officer | Option exercise | 20,100 | — | — | filing |
| 2026-01-08 | Oliveto Joseph· President and CEO | Sale | 43,000 | $2.25 | $96,750.00 | filing |
| 2026-01-07 | Oliveto Joseph· President and CEO | Sale | 500 | $2.25 | $1,125.00 | filing |
| 2025-12-15 | Oliveto Joseph· President and CEO | Sale | 133,054 | $2.32 | $308,685.28 | filing |
| 2025-12-15 | Nelson Jeffrey Edward· Chief Operating Officer | Sale | 58,007 | $2.32 | $134,576.24 | filing |
| 2025-12-15 | Bharucha David· Chief Medical Officer | Sale | 58,007 | $2.32 | $134,576.24 | filing |
| 2025-12-15 | Hasija Amit· CFO & EVP of Corp. Development | Sale | 58,007 | $2.32 | $134,576.24 | filing |
| 2025-12-15 | Muller Lorenz· Chief Commercial Officer | Sale | 53,566 | $2.32 | $124,273.12 | filing |
| 2025-12-12 | Bharucha David· Chief Medical Officer | Award | 100,000 | — | — | filing |
| 2025-12-12 | Nelson Jeffrey Edward· Chief Operating Officer | Award | 100,000 | — | — | filing |
| 2025-12-12 | Muller Lorenz· Chief Commercial Officer | Award | 100,000 | — | — | filing |
| 2025-12-12 | Hasija Amit· CFO & EVP of Corp. Development | Award | 100,000 | — | — | filing |
| 2025-12-12 | Oliveto Joseph· President and CEO | Award | 280,000 | — | — | filing |
| 2025-12-09 | Muller Lorenz· Chief Commercial Officer | Gift | 25,000 | $0.00 | $0.00 | filing |
| 2025-07-11 | Liebert Debra K. | Award | 16,666 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.